

References

1. Leong, Anthony S-Y, Cooper, Kumarason, Leong, F Joel W-M (2003). *Manual of Diagnostic Cytology* (2nd ed.). Greenwich Medical Media, Ltd. ISBN 1-84110-100-1. 79–80.
2. Lilja H (2003). "Biology of prostate-specific antigen". *Urology*. **62** (5 Suppl 1), PMID 14607215, 27-33.
3. Werny DM, Saraiya M, Gregg EW. (2006). Prostate-specific antigen values in diabetic and nondiabetic US men, 2001–2002. *Am J Epidemiol.*, 164, 978–983.
4. Baillargeon J, Pollock BH, Kristal AR, et al. (2005). The association of body mass index and prostate-specific antigen in a population-based study. *Cancer*, 103, 1092–5.
5. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED. (2005). Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. *Urology*, 65, 708–12.
6. Hutterer G, Perrotte P, Gallina A, et al. (2007). Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. *Eur J Cancer*, 43, 1180–7.
7. Atchison EA, Gridley G, Carreon JD, (2011). Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. *Int J Cancer*, 128, 635–643.
8. Kasper JS, Liu Y, Giovannucci E. (2009). Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. *Int J Cancer*, 124, 1398–1403.
9. Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, Huang WY, Weiss JM, Danforth KN, Grubb RL, 3rd, Andriole GL. (2008). Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. *Cancer Causes Control*, 19, 1267–1276.
10. Kasper JS, Giovannucci E. (2006). A meta-analysis of diabetes mellitus and the risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev.*, 15, 2056–2062.
11. Turner EL, Lane JA, Donovan JL, Metcalfe C, Neal DE, Hamdy FC, Martin RM. (2011). Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). *Int J Cancer*, 128, 440–446.
12. Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. (2009). Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? *Cancer Epidemiol Biomarkers Prev.*, 18, 1350–1356.
13. Werny DM, Saraiya M, Gregg EW. (2006) Prostate-specific antigen values in diabetic and nondiabetic US men, 2001–2002. *Am J Epidemiol.*, 164, 978–983.
14. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, Sauver JL, Jacobsen SJ, Sarma AV. (2011). The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County Study. *Urology*, 77, 137–141.
15. Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, Nakamura N. Serum prostate-specific antigen levels in men with type 2 diabetes. *Diabetes Care*, 2008; 31: 930–931.
16. Ando R, Nagaya T, Hashimoto Y, Suzuki S, Itoh Y, Umemoto Y, Ikeda N, Tozawa K, Kohri K, Tokudome S. (2008). Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004–2006. *Urology*, 72, 561–565.
17. Ochiai A, Fritsche HA, Babaian RJ. (2005). Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. *Urology*, 66, 819–823.
18. American Diabetes Association. (2016) 2. Classification and diagnosis of diabetes. *Diabetes Care.*, 39 Suppl 1:S13-22.
19. Cohen P, Peehl DM, Rosenfeld RG. (1994) The IGF axis in the prostate. *Horm Metab Res.*, 26, 81-4.
20. Oliver SE, Barrass B, Gunnell DJ, Donovan JL, Peters TJ, Persad RA, et al. (2004). Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. *Cancer Epidemiol Biomarkers Prev.*, 13, 163-5.
21. Giovannucci E. (2003). Nutrition, insulin, insulin-like growth factors and cancer. *Horm Metab Res.*, 35, 694-704.
22. Bruun L, Ekberg H, Bjørk T, Lilja H, Høglund P, Christensson A, et al. (2004). Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. *J Urol.*, 171, 1432-5.
23. Jayalath VH, Ireland C, Fleshner NE, Hamilton RJ, Jenkins DJ. (2016). The relationship between metformin and serum prostate-specific antigen levels. *Prostate*; 76, 1445-53.
24. Chang SL, Harshman LC, Presti JC Jr. (2010). Impact of common medications on serum total prostate-specific antigen levels: Analysis of the national health and nutrition examination survey. *J Clin Oncol*; 28, 3951-7.

25. Betancourt-Albrecht M, Cunningham GR. (2003). Hypogonadism and diabetes. *Int J Impot Res*; 15 Suppl 4, S14-20.
26. Barrett-Connor E, Khaw KT, Yen SS. (1990). Endogenous sex hormone levels in older adult men with diabetes mellitus. *Am J Epidemiol.*,132, 895–901.
27. Hutterer G, Perrotte P, Gallina A, Walz J, Jeldres C, Traumann M, Suardi N, Saad F, Benard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI. (2007). Body mass index does not predict prostatespecific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. *Eur J Cancer*, 43, 1180–1187.
28. Monath JR, McCullough DL, Hart LJ, Jarow JP. (1995). Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. *Urology.*, 46, 58–61.
29. Velicer CM, Dublin S, White E. (2007). Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. *Prostate Cancer Prostatic Dis.*, 10, 46–51.
30. Kubota Y, Seike K, Maeda S, Shinohara Y, Iwata M, Sugimoto N, *et al.* (2011). Relationship between prostate-specific antigen and obesity in prostate cancer screening: Analysis of a large cohort in Japan. *Int J Urol.*, 18. 72-5.

